Amgen Inc. (AMGN)
Health Care15 articles
Price chart
Why is AMGN moving today?
-0.4%AMGN is -0.4% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 6 hours ago
Amgen Inc. (AMGN) overview
Amgen is one of the world’s largest biotechnology companies.
AMGN is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Amgen Inc. trades on the NasdaqGS under the ticker symbol AMGN. The most recent market data puts the share price at about $432.49. That is down 0.35% on the session. At that price the company is worth roughly $233.82B.
Over the past 52 weeks, AMGN has traded between $288.00 and $447.03. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 26.9. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. AMGN also pays a dividend. It yields around 2.32% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 6 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch AMGN
AMGN is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each AMGN story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. AMGN is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves AMGN
- Earnings. AMGN reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from AMGN.
- Sector news. Health Care stocks often move together, so a rival's news can move AMGN too.
- Index weight. AMGN is big enough to move the S&P 500 on its own.
Market Mood
Latest AMGN news
David J. Taylor Buys Amgen, Home Depot Stocks; Sells Marathon
David J. Taylor has made notable changes to his investment portfolio by purchasing shares in Amgen (AMGN) and Home Depot (HD), while selling his stake in Marathon Petroleum (MPC). This adjustment highlights a shift in his investment strategy, reflecting his interest in biotechnology and home improvement sectors, while reducing his exposure to the energy sector.
Read More: David J. Taylor Buys Amgen, Home Depot Stocks; Sells Marathon
Amgen (AMGN) Shares Decline 5% Following Novartis Drug Trial Failure
Amgen Inc. (NASDAQ: AMGN) lost approximately $12 billion in market value after its stock fell about 5% to $415 on September 4, 2026. This decline was triggered by Novartis's announcement that its Lp(a)-lowering drug, pelacarsen, failed in a Phase 3 trial, jeopardizing the validity of similar drugs, including Amgen's olpasiran. Despite the drop, Amgen has other products driving value, such as MariTide, Repatha, and Tezspire, which provide some stock resilience. This is significant for investors considering the impact of trial results on biotech stock valuations and the importance of diversification in Amgen's portfolio.
Read More: Amgen (AMGN) Shares Decline 5% Following Novartis Drug Trial Failure
Amgen (AMGN) FY 2025 Revenue at $36.7 Billion with 9.9% Growth
Amgen (AMGN) reported nearly $36.7 billion in revenue for FY 2025, marking a growth of approximately 9.9% from the previous year. The company's net income reached around $7.7 billion, reflecting a net margin of 21%, up from 12.2% in 2024. Amgen's debt-to-equity ratio stands at roughly 6.3x, indicating a significantly higher level of debt relative to equity, while the current ratio is approximately 1.1x. Revolution Medicines (RVMD), contrastingly, reported zero revenue for FY 2025 and a net loss of about $1.1 billion as it develops cancer therapies. This information helps investors evaluate the financial stability of Biotech companies in their portfolios.
Read More: Amgen (AMGN) FY 2025 Revenue at $36.7 Billion with 9.9% Growth
Jim Cramer Advises Investors to Diversify Beyond AI Stocks
Jim Cramer stated that investors are focused too heavily on artificial intelligence stocks and should consider diversifying into other sectors over the next two months. He highlighted GE Aerospace's acquisition of Consolidated Precision Products for $11.75 billion, which could strengthen their supply chain and benefit Boeing. Cramer also mentioned fintech companies Robinhood and Affirm, with Affirm reporting 28 million active customers. He suggests energy infrastructure firms like Enbridge and Enterprise Products Partners may benefit with dividend yields over 5%. This advice is pertinent as investors look for growth opportunities outside AI stocks.
Read More: Jim Cramer Advises Investors to Diversify Beyond AI Stocks
Amgen (AMGN) SVP Rachna Khosla Sells $1.35M of Stock
Rachna Khosla, Senior Vice President at Amgen (AMGN), sold $1.35 million worth of the company’s stock. This sale highlights individual stock transactions by executives, which can indicate their confidence or outlook on their company's performance. While insider sales like this don’t always predict declines, they can reflect an executive's personal financial moves. Monitoring such transactions is important for ordinary investors as they can be signals of future company performance.
Read More: Amgen (AMGN) SVP Rachna Khosla Sells $1.35M of Stock
Amgen (AMGN) SVP Nancy Grygiel Disposes $1.19M in Stock
Nancy Grygiel, Senior Vice President and Chief Commercial Officer at Amgen (AMGN), sold $1.19 million worth of stock. This transaction adds to ongoing concerns among investors regarding insider selling trends at major corporations. The disposal of shares by a high-ranking executive could influence market perceptions and stock performance. Investors should monitor such insider activity as it may be indicative of executives' confidence in the company's future.
Read More: Amgen (AMGN) SVP Nancy Grygiel Disposes $1.19M in Stock
Amgen (AMGN) SVP Sells $1.56M in Stock after Option Exercise
An Amgen (AMGN) Senior Vice President sold $1.56 million worth of stock following an option exercise. This transaction indicates executive activity in the company's shares, which may signal confidence or liquidity management. The stock sale could impact investor perceptions regarding Amgen's stock performance. For investors, monitoring insider trading can provide insights into company health and executive sentiment.
Read More: Amgen (AMGN) SVP Sells $1.56M in Stock after Option Exercise
Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Pfizer (PFE) trades at 8x forward earnings and has a 7% dividend yield, positioning it as a cheaper option compared to Amgen's (AMGN) 17x rebuild multiple. In Q1 2026, Pfizer's oncology franchise generated $3.83 billion in revenue, a 9% year-over-year increase, driven by its Seagen deal and Padcev, which contributed $591 million, up 39%. In contrast, Amgen's key products saw significant declines, with Prolia down 34% and Enbrel down 37%. This dissonance in performance highlights the contrasting strategies, where Pfizer is monetizing existing assets while Amgen is working on rebuilding growth, impacting investor sentiment toward both companies.
Read More: Pfizer (PFE) Trades at 8x Earnings, Seagen Integration Drives Growth
Amgen (AMGN) Linked to 20 Deaths in Japan from Drug Usage
A reported 20 individuals in Japan have died following the administration of a drug developed by Amgen (AMGN). This incident raises concerns about the medication's safety and efficacy, potentially impacting Amgen's reputation and stock performance. Investors may closely monitor how this development influences regulatory scrutiny and market confidence in Amgen's products. These events could lead to increased volatility in AMGN shares as more information becomes available.
Read More: Amgen (AMGN) Linked to 20 Deaths in Japan from Drug Usage
Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning
Amgen (AMGN) experienced a decline in its stock price following a warning from Kissei Pharmaceutical regarding liver risks associated with Tavneos. Specific data on the stock price drop or percentage changes was not provided. This warning may lead to investor concerns about potential market implications for Amgen, particularly if regulatory actions arise due to safety assessments. Kissei's caution could also impact the competitive landscape for treatments related to liver conditions.
Read More: Amgen (AMGN) Stock Drops After Kissei's Tavneos Liver Risk Warning
Amgen (AMGN) Reports 24% Growth Driven by Key Factors
Amgen (AMGN) announced a 24% expansion in Q1 2026, attributing this growth to six main drivers. This performance reflects a significant increase in demand and improved operational efficiencies. Such growth may positively influence market perceptions, especially among investors looking for robust earnings potential. Monitoring these growth drivers could help analysts assess Amgen's future performance and its impact on the biotechnology sector.
Read More: Amgen (AMGN) Reports 24% Growth Driven by Key Factors
Amgen (AMGN) Q1 2026 Earnings Beat EPS Forecast
Amgen (AMGN) reported its Q1 2026 earnings, exceeding EPS forecasts. The company achieved earnings of $XYZ per share, surpassing analysts' expectations. Despite the earnings beat, AMGN's stock experienced a dip of X% following the announcement. This reaction may reflect investor concerns about future performance or guidance. The report suggests mixed sentiment among investors regarding Amgen's prospects.
Read More: Amgen (AMGN) Q1 2026 Earnings Beat EPS Forecast
Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Novartis (NVS), Amgen (AMGN), and Eli Lilly (LLY) are conducting late-stage trials for drugs aimed at reducing lipoprotein(a) or Lp(a) levels to prevent heart attacks. Current experimental drugs are shown to reduce Lp(a) by over 80%. Consensus estimates suggest these drugs could generate annual sales of $5.6 billion by 2032. The first results from Novartis' Phase 3 Horizon trial are expected later this year, which will significantly influence the market potential of these therapies.
Read More: Novartis (NVS) drug trials target Lp(a) for heart disease prevention
Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy
Zai Lab (ZLAB) and Amgen (AMGN) have announced a partnership to evaluate a combination therapy for lung cancer. This collaboration is aimed at improving treatment options for patients and could signify advancements in oncology therapies. The outcomes of this evaluation may impact both companies' stock performance and the broader market perception of lung cancer treatments. Investors will be watching the developments closely given the increasing focus on cancer therapies within the biopharmaceutical sector.
Read More: Zai Lab (ZLAB) and Amgen (AMGN) Collaborate on Lung Cancer Therapy
Comparative Analysis: Novo Nordisk vs. Amgen in the Weight Loss Market
In the competitive weight loss stock sector, Novo Nordisk and Amgen are prominent players, each vying for market share with innovative treatments. Novo Nordisk has gained traction with its GLP-1 receptor agonists, while Amgen is focusing on different therapeutic approaches. The success of these drugs is critical, as obesity medications are expected to reshape market dynamics with growing demand. Investors should note the recent performance metrics showing Novo's strong revenue growth compared to Amgen, signaling potential investment opportunities in this health-focused segment.
Read More: Comparative Analysis: Novo Nordisk vs. Amgen in the Weight Loss MarketMore Health Care stocks
Frequently asked questions
Is Amgen Inc. in the S&P 500?
Yes. Amgen Inc. trades as AMGN and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is AMGN in?
AMGN sits in the Health Care sector of the S&P 500.
Where can I find the latest AMGN news?
Right here. This page collects recent AMGN news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Amgen Inc.'s stock price?
AMGN last traded at about $432.49. Prices move all through the session, so this is the latest quote rather than a live one.
What is Amgen Inc.'s market cap?
AMGN is worth roughly $233.82B. Market cap is the share price times the number of shares outstanding.
What is AMGN's P/E ratio?
AMGN trades at a trailing P/E ratio of about 26.9. The ratio compares the share price with earnings per share over the past year.